{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:39:02Z","timestamp":1792273142633,"version":"4.4.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["MAT2014-59134-R"],"award-info":[{"award-number":["MAT2014-59134-R"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Portuguese Science and Technology Foundation, Ministry of Science and Education"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ejpb.2016.10.013","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T14:32:38Z","timestamp":1477319558000},"page":"58-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"special_numbering":"C","title":["Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye \u2013 Part II - Ocular drug-loaded lipid nanoparticles"],"prefix":"10.1016","volume":"110","author":[{"given":"E.","family":"S\u00e1nchez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Espina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Doktorovova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.B.","family":"Souto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2016.10.013_b0005","first-page":"371","article-title":"Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles","volume":"10","author":"Hwang","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2016.10.013_b0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2009.06.020","article-title":"Liposome coated with low molecular weight Chitosan and its potential use in ocular drug delivery","volume":"379","author":"Li","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0015","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jps.22422","article-title":"Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery","volume":"100","author":"Abdelkader","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/02652040600612439","article-title":"Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC","volume":"23","author":"Souto","year":"2006","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2016.10.013_b0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/02652040500435295","article-title":"Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization","volume":"23","author":"Souto","year":"2006","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2016.10.013_b0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","article-title":"Nanostructured lipid matrices for improved microencapsulation of drugs","volume":"242","author":"M\u00fcller","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery \u2013 a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/157016311796799062","article-title":"20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications","volume":"8","author":"M\u00fcller","year":"2011","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.ejpb.2016.10.013_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2014.02.005","article-title":"Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers \u2013 a systematic review of in vitro data","volume":"87","author":"Doktorovova","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2016.10.013_b0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles Production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2016.10.013_b0060","doi-asserted-by":"crossref","first-page":"025101","DOI":"10.1088\/0957-4484\/21\/2\/025101","article-title":"Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement","volume":"21","author":"Shen","year":"2010","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejpb.2016.10.013_b0065","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/10717544.2010.483257","article-title":"Solid lipid nanoparticles for ocular drug delivery","volume":"17","author":"Seyfoddin","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2016.10.013_b0070","unstructured":"M.R. Gasco, G.P. Zara, M.F. Saettone, Pharmaceutical Compositions Suitable for the Treatment of Ophthalmic Diseases, WO\/2004\/039351, 2004."},{"key":"10.1016\/j.ejpb.2016.10.013_b0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijpharm.2006.02.050","article-title":"Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity","volume":"317","author":"Cortesi","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0080","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijpharm.2013.11.025","article-title":"Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity","volume":"461","author":"Fangueiro","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/jop.2012.0128","article-title":"Lipid nanoparticles as drug\/gene delivery systems to the retina","volume":"29","author":"del Pozo-Rodr\u00edguez","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2016.10.013_b0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/02713681003760168","article-title":"Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs","volume":"35","author":"Souto","year":"2010","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2016.10.013_b0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijpharm.2014.04.061","article-title":"Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles","volume":"470","author":"Leonardi","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.17554\/j.issn.2409-5680.2015.01.29","article-title":"Lipid nanoparticles for ocular drug delivery","volume":"1","author":"Okur","year":"2015","journal-title":"Int. J. Ophthal. Res."},{"key":"10.1016\/j.ejpb.2016.10.013_b0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/09273940490883671","article-title":"Treatment of ocular inflammation","volume":"12","author":"Jabs","year":"2004","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0110","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijpharm.2010.03.034","article-title":"Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications","volume":"393","author":"Ara\u00fajo","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0115","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.nano.2011.10.015","article-title":"Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies","volume":"8","author":"Ara\u00fajo","year":"2012","journal-title":"Nanomed. Nanotechnol., Biol. Med."},{"key":"10.1016\/j.ejpb.2016.10.013_b0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.colsurfb.2011.06.025","article-title":"Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye","volume":"88","author":"Ara\u00fajo","year":"2011","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.ejpb.2016.10.013_b0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1208\/s12248-008-9024-9","article-title":"Topical ocular delivery of NSAIDs","volume":"10","author":"Ahuja","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2016.10.013_b0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00002018-200225040-00002","article-title":"Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review","volume":"25","author":"Gaynes","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejpb.2016.10.013_b0135","first-page":"157","article-title":"Design and optimization of NSAID loaded nanoparticles","volume":"20","author":"Sashmal","year":"2007","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0140","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/jps.20685","article-title":"Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration","volume":"95","author":"Vega","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0145","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1002\/jps.24101","article-title":"Design of nanosuspensions and freeze-dried PLGA nanoparticles as a novel approach for ophthalmic delivery of pranoprofen","volume":"103","author":"Abrego","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0150","first-page":"609","article-title":"Conjugation of cell-penetrating peptides with poly (lactic-co-glycolic acid) -polyethylene glycol nanoparticles improves ocular drug delivery","volume":"10","author":"Vasconcelos","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2016.10.013_b0155","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijpharm.2007.12.007","article-title":"Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct","volume":"355","author":"Attama","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2008.07.017","article-title":"A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers","volume":"363","author":"Li","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.colsurfb.2010.07.029","article-title":"Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC","volume":"81","author":"Gonzalez-Mira","year":"2010","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.ejpb.2016.10.013_b0170","doi-asserted-by":"crossref","first-page":"045101","DOI":"10.1088\/0957-4484\/22\/4\/045101","article-title":"Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery","volume":"22","author":"Gonzalez-Mira","year":"2011","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejpb.2016.10.013_b0175","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/jps.22784","article-title":"Improved and safe transcorneal delivery of Flurbiprofen by NLC and NLC-based hydrogels","volume":"101","author":"Gonz\u00e1lez-Mira","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2010.10.013","article-title":"Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system","volume":"403","author":"Luo","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0185","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/jop.2012.0069","article-title":"Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation","volume":"29","author":"Hippalgaonkar","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2016.10.013_b0190","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of Immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2016.10.013_b0195","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1023\/A:1013671819604","article-title":"Cyclosporine A formulation affects its ocular distribution in rabbits","volume":"19","author":"Kuwano","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.10.013_b0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/02652040902846883","article-title":"Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery","volume":"27","author":"Ba\u015faran","year":"2010","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2016.10.013_b0205","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: a pharmaceutical challenge","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0378-5173(02)00268-5","article-title":"Incorporation of cyclosporin A in solid lipid nanoparticles (SLN)","volume":"241","author":"Ugazio","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0215","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ejpb.2007.07.006","article-title":"Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation","volume":"68","author":"M\u00fcller","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0220","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijpharm.2008.07.028","article-title":"Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity","volume":"364","author":"Gokce","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0225","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3109\/02713680903261405","article-title":"Cyclosporine A-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes","volume":"34","author":"G\u00f6k\u00e7e","year":"2009","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2016.10.013_b0230","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3109\/02652048.2010.517854","article-title":"Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems","volume":"27","author":"Sandri","year":"2010","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2016.10.013_b0235","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1773-2247(12)50016-X","article-title":"Solid lipid nanoparticles prepared by coacervation method as vehicles for ocular cyclosporine","volume":"22","author":"Battaglia","year":"2012","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2016.10.013_b0240","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/OPTH.S5778","article-title":"Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics","volume":"3","author":"Bertino","year":"2009","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejpb.2016.10.013_b0245","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/bjo.87.7.834","article-title":"Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases","volume":"87","author":"Bourcier","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2016.10.013_b0250","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/jps.10368","article-title":"Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin","volume":"92","author":"Cavalli","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0255","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0378-5173(02)00080-7","article-title":"Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin","volume":"238","author":"Cavalli","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0260","first-page":"683","article-title":"Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design","volume":"6","author":"Hao","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2016.10.013_b0265","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.4028\/www.scientific.net\/AMR.236-238.2917","article-title":"Preparation and characterization of Azithromycin-loaded nanostructured lipid carriers","volume":"236\u2013238","author":"Wu","year":"2011","journal-title":"Adv. Mater. Res."},{"key":"10.1016\/j.ejpb.2016.10.013_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2004.01.005","article-title":"Fluoroquinolones: mechanism of action, classification, and development of resistance","volume":"49","author":"Blondeau","year":"2004","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejpb.2016.10.013_b0275","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejps.2014.07.013","article-title":"Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis","volume":"63","author":"\u00dcst\u00fcnda\u01e7-Okur","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0280","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijbiomac.2015.12.077","article-title":"Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: optimization, in vitro release, ocular tolerance, and antibacterial activity","volume":"85","author":"Baig","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2016.10.013_b0285","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/10611860903338462","article-title":"Preparation, characterization, and evaluation of Gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system","volume":"18","author":"Kalam","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2016.10.013_b0290","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/jbm.a.34453","article-title":"Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin","volume":"101 A","author":"Kalam","year":"2013","journal-title":"J. Biomed. Mater. Res. - Part A"},{"key":"10.1016\/j.ejpb.2016.10.013_b0295","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/jbm.a.34467","article-title":"Part II: Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops","volume":"101 A","author":"Kalam","year":"2013","journal-title":"J. Biomed. Mater. Res. - Part A"},{"key":"10.1016\/j.ejpb.2016.10.013_b0300","first-page":"289","article-title":"Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspective","volume":"2","author":"\u00dcner","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2016.10.013_b0305","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-3659(99)00192-3","article-title":"Acyclovir-containing liposomes for potential ocular delivery Corneal penetration and absorption","volume":"63","author":"Law","year":"2000","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2016.10.013_b0310","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1517\/17425240802450340","article-title":"Acyclovir delivery systems","volume":"5247","author":"Cortesi","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2016.10.013_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03639045.2012.665460","article-title":"Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir","volume":"39","author":"Seyfoddin","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0320","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1517\/14656566.2.11.1849","article-title":"Pharmacotherapy of fungal eye infections","volume":"2","author":"Manzouri","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejpb.2016.10.013_b0325","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijpharm.2015.08.088","article-title":"Lipid-polyethylene glycol based nano-ocular formulation of ketoconazole","volume":"495","author":"Kakkar","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0330","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/10837450.2014.882935","article-title":"Development and characterization of itraconazole-loaded solid lipid nanoparticles for ocular delivery","volume":"20","author":"Mohanty","year":"2015","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2016.10.013_b0335","doi-asserted-by":"crossref","unstructured":"J.H. Gurwitz, R.J. Glynn, M. Monane, D.E. Eveitt, D. Gilden, N. Smith, Treatment for Glaucoma\u202f: Adherence by the Elderly, 1992.","DOI":"10.2105\/AJPH.83.5.711"},{"key":"10.1016\/j.ejpb.2016.10.013_b0340","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","article-title":"Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review","volume":"112","author":"Olthoff","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2016.10.013_b0345","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0378-5173(94)00339-7","article-title":"Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair","volume":"117","author":"Cavalli","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0350","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3109\/10837450.2012.705298","article-title":"Preparation and characterization of polymeric and lipid nanoparticles of pilocarpine HCl for ocular application","volume":"18","author":"L\u00fctfi","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2016.10.013_b0355","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/02713680903017500","article-title":"Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea","volume":"34","author":"Attama","year":"2009","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2016.10.013_b0360","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/1567201811310050001","article-title":"Betaxolol Hydrochloride loaded Chitosan nanoparticles for ocular delivery and their antiglaucoma efficacy","volume":"10","author":"Kunal","year":"2013","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2016.10.013_b0365","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clay.2015.10.028","article-title":"Preparation and in vitro study of lipid nanoparticles encapsulating drug loaded montmorillonite for ocular delivery","volume":"119","author":"Hou","year":"2016","journal-title":"Appl. Clay Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0370","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/02652048.2010.539304","article-title":"A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide","volume":"28","author":"Li","year":"2011","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2016.10.013_b0375","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijpharm.2013.03.018","article-title":"Preformulation study of methazolamide for topical ophthalmic delivery: physicochemical properties and degradation kinetics in aqueous solutions","volume":"448","author":"Jiang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0380","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/08982104.2014.891231","article-title":"Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design","volume":"24","author":"Wang","year":"2014","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejpb.2016.10.013_b0385","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/1061186X.2014.939983","article-title":"Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study","volume":"22","author":"Wang","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2016.10.013_b0390","first-page":"2483","article-title":"Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide","volume":"7","author":"Youshia","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2016.10.013_b0395","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.exer.2006.10.018","article-title":"Melatonin in the eye: implications for glaucoma","volume":"84","author":"Lundmark","year":"2007","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2016.10.013_b0400","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neulet.2011.02.056","article-title":"Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse","volume":"494","author":"Alcantara-Contreras","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejpb.2016.10.013_b0405","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijpharm.2014.11.032","article-title":"Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit","volume":"478","author":"Leonardi","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0410","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2174\/0929867322666150209152259","article-title":"Lipid nanocarriers (LNC) and their applications in ocular drug delivery","volume":"22","author":"Puglia","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejpb.2016.10.013_b0415","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.colsurfb.2014.09.042","article-title":"Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation","volume":"123","author":"Fangueiro","year":"2014","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.ejpb.2016.10.013_b0420","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3109\/03639045.2013.795582","article-title":"Preparation and evaluation of charged solid lipid nanoparticles of tetrandrine for ocular drug delivery system: pharmacokinetics, cytotoxicity and cellular uptake studies","volume":"40","author":"Li","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0425","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/03639045.2010.522193","article-title":"Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo","volume":"37","author":"Liu","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0430","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1002\/jps.23251","article-title":"Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability","volume":"101","author":"Liu","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0435","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijpharm.2013.07.032","article-title":"Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology","volume":"454","author":"Zhang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0440","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijpharm.2014.05.030","article-title":"Enhanced cellular uptake and anti-proliferating effect of chitosan hydrochlorides modified genistein loaded NLC on human lens epithelial cells","volume":"471","author":"Zhang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0445","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.colsurfb.2013.09.059","article-title":"Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery","volume":"114","author":"Hao","year":"2014","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.ejpb.2016.10.013_b0450","doi-asserted-by":"crossref","first-page":"18706","DOI":"10.1073\/pnas.1007644107","article-title":"Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa","volume":"107","author":"Strettoi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2016.10.013_b0455","first-page":"2821","article-title":"Ocular gene therapy: quo vadis?","volume":"41","author":"Hauswirth","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0460","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijpharm.2014.02.038","article-title":"A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases","volume":"465","author":"Apaolaza","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0465","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/jfb6020379","article-title":"Lipid nanoparticles for ocular gene delivery","volume":"6","author":"Wang","year":"2015","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.ejpb.2016.10.013_b0470","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/0250-474X.57282","article-title":"Solid lipid nanoparticles: a modern formulation approach in drug delivery system","volume":"71","author":"Mukherjee","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.10.013_b0475","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2008.04.023","article-title":"Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells","volume":"360","author":"del Pozo-Rodr\u00edguez","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.10.013_b0480","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ejpb.2011.06.005","article-title":"Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway","volume":"79","author":"Delgado","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116307275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116307275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T23:46:22Z","timestamp":1657496782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641116307275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":96,"alternative-id":["S0939641116307275"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2016.10.013","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye \u2013 Part II - Ocular drug-loaded lipid nanoparticles","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2016.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}